Abstract
Auranofin, an oral chrysotherapeutic agent effective in the treatment of rheumatoid arthritis (RA), was found to be a potent, noncytotoxic inhibitor of IgG-RF immune complex-induced lysosomal enzyme release (LER) from human leukocytes. At a concentration of 1 μg Au/ml (5μM), auranofin produced a marked reduction inβ-glucuronidase (100%), acid phosphatase (88%), and lysozyme (72%) release. In contrast, gold sodium thiosulfate (GST, an injectable gold compound) had no inhibitory activity on LER at equivalent gold concentrations (i.e., 1μg Au/ml) and only modest activity (< 36% inhibition) at concentrations as high as 40μg Au/ml. The 50% inhibitory dose (ID50) of auranofin on LER was calculated to be 3–4μM (0.6–0.8μg Au/ml). Blood gold levels in auranofin-treated RA patients were found to be within the range required for in vitro inhibition of LER, and correlated with decreases in IgG, RF titers, and IgG-RF immune-complex formation in vitro. These results suggest that the therapeutic action of auranofin may be caused, at least in part, by inhibition of LER and/or decreases in immune-complex formation.
Similar content being viewed by others
References
Chayen, J., andL. Bitensky. 1971. Lysosomal enzymes and inflammation.Ann. Rheum. Dis. 30:522.
Weissmann, G., R.B. Zurier, P.J. Spieler, andI.M. Goldstein. 1971. Mechanism of lysosomal enzyme release from leukocytes exposed to immune-complexes and other particles.J. Exp. Med. 134:149.
Persellin, R.H., andM. Ziff. 1966. The effect of gold salt on lysosomal enzymes of the peritoneal macrophage.Arthritis Rheum. 9:57.
Ennis, R.S., J.L. Granda, andA.S. Posner. 1968. Effect of gold salts and other drugs on the release and activity of lysosomal hydrolases.Arthritis Rheum. 11:756.
Perper, R.J., andA.L. Oronsky. 1974. Enzyme release from human leukocytes and degradation of cartilage matrix. Effects of antirheumatic drugs.Arthritis Rheum. 17:47.
Finkelstein, A.E., D.T. Walz, V. Batista, M. Mizraji, F. Roisman, andA. Misher. 1976. Auranofin. New oral gold compound for treatment of rheumatoid arthritis.Ann. Rheum. Dis. 35:251.
Berglöf, F.-E., K.Berglöf, and D.T.Walz. 1977. Auranofln: An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis.Arthritis Rheum. (in press).
DiMartino, M.J., D.T. Walz, C.E. Wolff, andW.A. Mann. 1974. Inhibition of lysosomal enzyme release from rat leukocytes by a new gold compound-SK & F D-39162.Fed. Proc. 33:558.
Walz, D.T., M.J. DiMartino, L.W. Chakrin, B.M. Sutton, andA. Misher. 1976. Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: SK & F D-39162.J. Pharmacol. Exp. Ther. 197:142.
DiMartino, M.J., andD.T. Walz. 1977. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent.Inflammation 2:131.
Hanks, J.M., andH. Wallace. 1958. Determination of cell viability.Proc. Soc. Exp. Biol. Med. 98:188.
Singer, J.M., andC.M. Plotz. 1956. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.Am. J. Med. 21:888.
Lowry, O.H., N.J. Rosebrough, A.L. Farr, andR.J. Randall. 1951. Protein measurement with the folin phenol reagent.J. Biol. Chem. 193:265.
Lorber, A., R.L. Cohen, C.C. Chang, andH.E. Anderson. 1968. Gold determination in biological fluids by atomic absorption spectrophotometry: Application to chrysotherapy in rheumatoid arthritis patients.Arthritis Rheum. 11:170.
Fishman, W.H., K. Kato, C.L. Anstiss, andS. Green. 1967. Human serum β-glucuronidase; its measurement and some of its properties.Clin. Chim. Acta 15:435.
Litwack, G. 1955. Photometric determination of lysozyme activity.Proc. Soc. Exp. Biol. Med. 89, 401.
Andersch, M.A., andA.J. Sczcypinski. 1947. Use of P-nitrophenylphosphate as the substrate in determination of serum acid phosphatase.Am. J. Clin. Pathol. 17:571.
Kino, J. 1959. A routine method for the estimation of lactic dehydrogenase activity.J. Med. Lab. Technol. 16:265.
Cats, G.J., M. Lafeber, andF. Klein. 1975. Immunoglobulin phagocytosis by granulocytes from sera and synovial fluids in various rheumatoid and nonrheumatoid diseases.Ann. Rheum. Dis. 34:146.
Wright, D.G., andS.E. Malawista. 1973. Mobilization and extracellular release of granular enzymes from human leucocytes during phagocytosis.Arthritis Rheum. 16:749.
Author information
Authors and Affiliations
Additional information
SK&F D-39162 (2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranosato-S) (triethylphosphine) Gold.
Rights and permissions
About this article
Cite this article
Finkelstein, A.E., Roisman, F.R. & Walz, D.T. Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes. Inflammation 2, 143–150 (1977). https://doi.org/10.1007/BF00918676
Issue Date:
DOI: https://doi.org/10.1007/BF00918676